Christopher J. Sobecki Buys 99,249 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock

Share on StockTwits

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Christopher J. Sobecki bought 99,249 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was acquired at an average cost of $2.41 per share, with a total value of $239,190.09. Following the transaction, the director now owns 13,645 shares of the company’s stock, valued at $32,884.45. The purchase was disclosed in a filing with the SEC, which is available at this link.

LXRX opened at $3.45 on Friday. Lexicon Pharmaceuticals, Inc. has a 1 year low of $1.13 and a 1 year high of $11.51. The stock has a fifty day moving average price of $1.58 and a 200 day moving average price of $4.92.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.13). The company had revenue of $9.68 million during the quarter, compared to analysts’ expectations of $28.52 million. The company’s revenue was down 29.9% on a year-over-year basis. During the same period last year, the firm posted ($0.33) earnings per share. As a group, analysts predict that Lexicon Pharmaceuticals, Inc. will post 0.69 earnings per share for the current year.

LXRX has been the subject of several recent analyst reports. BidaskClub raised Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday. Gabelli raised Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.00 target price for the company in a research report on Wednesday, September 11th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, July 3rd. Wedbush reaffirmed an “outperform” rating and issued a $17.00 target price (down previously from $35.00) on shares of Lexicon Pharmaceuticals in a research report on Thursday, August 1st. Finally, Stifel Nicolaus cut Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their target price for the stock from $10.00 to $4.00 in a research report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $6.70.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in Lexicon Pharmaceuticals by 217.5% during the second quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after purchasing an additional 59,685 shares during the last quarter. Clearbridge Investments LLC boosted its position in Lexicon Pharmaceuticals by 3.4% during the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after purchasing an additional 42,540 shares during the last quarter. Wedbush Securities Inc. boosted its position in Lexicon Pharmaceuticals by 33.0% during the second quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 48,182 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in Lexicon Pharmaceuticals by 1.8% during the first quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock valued at $3,061,000 after purchasing an additional 9,615 shares during the last quarter. Finally, Wealth & Pension Services Group Inc. acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at $60,000. 98.87% of the stock is owned by hedge funds and other institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: Quantitative Easing

Insider Buying and Selling by Quarter for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

OFG Bancorp  Short Interest Up 17.8% in September
OFG Bancorp Short Interest Up 17.8% in September
$42.62 Million in Sales Expected for Livongo Health  This Quarter
$42.62 Million in Sales Expected for Livongo Health This Quarter
Blox  Trading Up 6.3% Over Last Week
Blox Trading Up 6.3% Over Last Week
Evoke Pharma Inc  Sees Significant Increase in Short Interest
Evoke Pharma Inc Sees Significant Increase in Short Interest
Getinge  Stock Price Passes Below Two Hundred Day Moving Average of $134.40
Getinge Stock Price Passes Below Two Hundred Day Moving Average of $134.40
GelTech Solutions  Stock Crosses Below 200-Day Moving Average of $0.17
GelTech Solutions Stock Crosses Below 200-Day Moving Average of $0.17


© 2006-2019 Ticker Report